Last reviewed · How we verify
Cyclosporine Vehicle
Cyclosporine is an immunosuppressant that inhibits T-cell activation by blocking calcineurin, thereby reducing inflammatory responses in the eye.
Cyclosporine is an immunosuppressant that inhibits T-cell activation by blocking calcineurin, thereby reducing inflammatory responses in the eye. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.
At a glance
| Generic name | Cyclosporine Vehicle |
|---|---|
| Sponsor | Allergan |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Cyclosporine suppresses the production of inflammatory cytokines by T lymphocytes through calcineurin inhibition, which prevents the transcription of IL-2 and other pro-inflammatory mediators. In ophthalmic formulations, it reduces ocular surface inflammation and increases tear production, making it effective for dry eye disease where immune-mediated inflammation is a primary pathogenic mechanism.
Approved indications
- Dry eye disease (keratoconjunctivitis sicca)
- Ocular surface inflammation
Common side effects
- Ocular irritation / burning
- Conjunctival hyperemia
- Blurred vision
- Foreign body sensation
Key clinical trials
- Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction (PHASE4)
- Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks (PHASE4)
- Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PHASE3)
- Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears
- A Study of the Efficacy and Safety of Cyclosporin Ophthalmic Gel in Subjects With Moderate to Severe Dry Eye Disease (PHASE3)
- A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease (PHASE2)
- 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin) (PHASE3)
- Evaluation of Safety & Efficacy for the Prevention of Ocular GVHD With Ophthalmic Tacrolimus vs Cyclosporine in Allo-HSCT (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclosporine Vehicle CI brief — competitive landscape report
- Cyclosporine Vehicle updates RSS · CI watch RSS
- Allergan portfolio CI